UNSPSC 51273945: Lidocaine/tetracaine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.

UNSPSC 51273945 Lidocaine/tetracaine, a Commodity code, nominally covers local anesthetic pharmaceutical products, but recent state and local solicitations show minimal activity directly aligned with this specific drug compound. The recent opportunities block contains three posted solicitations: one from Seminole County, Florida seeking naloxone and drug deactivation systems; one from the Texas Health and Human Services Commission conducting market research on direct-to-manufacturer prescription programs; and one from the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) establishing master agreements for generic multi-source pharmaceuticals and over-the-counter products. None of these opportunities explicitly target lidocaine or tetracaine procurement. The MMCAP RFP is the broadest in scope, covering thousands of generic pharmaceutical products with specific National Drug Codes through a cooperative purchasing vehicle open to multiple state and local jurisdictions, but the lidocaine/tetracaine code does not appear to map directly to the work being solicited.

Geographic activity appears concentrated in the Upper Midwest and Sun Belt where recent RFP and RFI postings occurred, with MMCAP (Minnesota) serving multiple states including Oregon, Seminole County in Florida, and Texas HHS conducting exploratory procurement. The MMCAP RFP due March 26, 2026 is the most mature opportunity, requiring proposals through the ePro system with evaluation weighted 75 percent on price competitiveness and 25 percent on administrative and operational criteria; awarded vendors must maintain relationships with AmerisourceBergen, Cardinal Health, or Morris & Dickson and comply with cGMP and Drug Supply Chain Security Act standards. The Seminole County IFB (due July 26, 2023 as posted) seeks annual procurement of naloxone and drug deactivation systems with quarterly deliveries, while the Texas HHS RFI (response deadline April 3, 2026) functions as preliminary market intelligence gathering on direct-to-manufacturer prescription capabilities rather than formal competitive solicitation. The code shows little relevant recent activity and represents a mismatch between the pharmaceutical taxonomy and current state and local buying patterns, which favor broader multi-source generics procurement and public-health-focused naloxone programs over targeted single-compound anesthetic procurement.